Trial · NCT06732258
Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
NCT06732258, Phase 1, Withdrawn, Sichuan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC. Trials, record NCT06732258. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06732258
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
- NCT number
- NCT06732258
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- Sichuan University
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Low-dose radiotherapy, Tifcemalimab injection, Toripalimab, Cisplatin, Carboplatin, Etoposide
- First posted
- 2024-12-13
- Last updated
- 2026-04-29
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with Dose-limiting Toxicitys (DLTs) | up to 21 days after the first dose | |
| Secondary | Objective response rate (ORR) | up to 2 years | Defined as the proportion of subjects achieving a complete response (CR) or partial response (PR) during treatment. |
| Secondary | Disease control rate (DCR) | up to 2 years | Defined as the proportion of subjects achieving complete response (CR) or partial response (PR) or stable disease (SD) during treatment. |
| Secondary | Duration of response (DOR) | up to 2 years | Defined as the time from the first documented response (CR or PR) to the first documented disease progression or death, whichever came first. |
| Secondary | Progression-free survival (PFS) | up to 2 years | Defined as the time from enrollment to the first documented disease progression or death from any cause, whichever came first. |
| Secondary | Overall Survival (OS) | up to 2 years | Defined as the time from enrollment to death due to any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06732258
GET https://conductscience.org/api/trials/v1/NCT06732258/registered